

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 208 849 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
29.05.2002 Bulletin 2002/22

(51) Int Cl.7: **A61K 38/48**, A61P 29/00,
A61P 37/00, A61P 37/08,
A61K 35/78

(21) Application number: **00125986.0**

(22) Date of filing: **28.11.2000**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Maurer, Rainer**
14129 Berlin (DE)
• **Eschmann, Klaus**
66271 Kleinblittersdorf (DE)

(71) Applicant: **URSAPHARM Arzneimittel GmbH &
Co. KG**
D-66129 Saarbrücken (DE)

(74) Representative: **Becker Kurig Straus**
Patentanwälte
Bavariastrasse 7
80336 München (DE)

(54) **Use of bromelain for the treatment of inflammatory diseases and for adjuvant therapy during wound healing process**

(57) The present application pertains to the use of bromelain preparing a medicament for increasing the IL-

8 level in an individual so as to reduce or prevent inflammation in said individual and as an adjuvant therapy during wound healing processes.




FIG. 1

Description

[0001] The present invention relates to the use of bromelain and components thereof for the manufacture of a medicament for increasing the IL-8 level in an individual so as to reduce or prevent inflammatory diseases in said individual and to use it as an adjuvant therapy to promote wound healing processes.

[0002] Inflammation, or the inflammatory process, respectively involves several biological reactions, proceeding in three successive phases: the degenerative phase, the vascular phase, and the healing phase.

[0003] In the degenerative phase, the affected cells become swollen. The cytoplasm of affected cells becomes vacuolized and an enlargement and fragmentation of cell nuclei can be observed. As some of the platelets in the damaged blood vessels disintegrate, mediators acting on sympathetic nerve endings are released.

[0004] Subsequently, in the vascular phase changes in the blood vessels can be observed. In particular, an extensive migration and activity of so-called inflammatory cells (granulocytes, particularly neutrophils, lymphocytes, macrophages and monocytes) and clearing of cellular debris and degenerated cells occur during this phase. As the capillary network and the postcapillary venules become flooded, congested and engorged by blood in active hyperemia and as a number of capillaries proliferate, a reddish appearance of inflamed tissue results.

[0005] In the last phase, the healing phase, the inflammation begins to subside and repair of wound starts.

[0006] Often inflammatory processes result in the formation of oedema, an accumulation of liquid in inter-tissue spaces, as the transport activity with respect to osmotic active compounds is locally decreased in the inflamed areas. Closely related to this phenomenon are swellings observed after operations or traumata, often causing considerable pain to the patient.

[0007] On a molecular basis, a plethora of active mediators are involved in the development of inflammation, such as e.g. cytokines and in particular interleukin 1- α , interleukin 1- β , interleukin 6, tumor necrosis factor α and β , interleukin 8 (IL-8).

[0008] In particular, IL-8 has been found to attract granulocytes and neutrophils towards an inflamed area and to activate the functional capacities of granulocytes, such as phagocytosis, cytotoxicity, chemotaxis etc.. IL-8 is a non-glycosylated protein of 8 kDa having 72 amino acids and is also known as ANAP (anionic neutrophil activating peptide), GCP (granulocyte chemotactic peptide), LCF (lymphocyte chemotactic factor) and LIF (leukocyte inhibitory factor). IL-8 is produced in various cells e.g. monocytes/macrophages, granulocytes, T-cells, fibroblasts or endothelium cells as response to proinflammatory stimuli, such as IL-1, TNF, LPS and viruses.

[0009] Conventionally, the treatment of inflammatory conditions and oedema utilized an oral administration of non-steroidal anti-inflammatory drugs (NSAIDS), such

as e.g. acetylsalicylic acid, phenylbutazone, diclofenac or indometacine. However, these agents exhibit several, sometimes severe secondary effects, e.g. gastro-intestinal problems and adverse effects on gastroenteric mucosa.

[0010] To overcome these drawbacks the art provided additional agents for treating inflammation. In this respect the WO 98/13057 discloses the use of a composition containing a Tripterygium wilfordii Hook F root preparation that has anti-inflammatory properties. Yet, since this composition also exhibits immunosuppressive activity the effect thereof in treating inflammation was rather poor. Further, in EP 100 94 04 the use of pADPRT (poly-ADP ribose polymerase) inhibitory compounds are proposed for the treatment of inflammatory diseases. However, also in this case unwanted secondary effects occur upon administration.

[0011] Therefore, there is a need in art for additional, well tolerated agents for treating inflammatory diseases and/or inflammatory diseases that do not show unwanted side effects.

[0012] Consequently, according to a first aspect the present invention provides the use of bromelain or one or more components thereof for the manufacture of a medicament for increasing the IL-8 level in an individual.

[0013] Bromelain, an extract from pineapple stem (*Ananas comosus*), is a mixture of various compounds, such as enzymes, e.g. proteases, phosphatases, peroxidases, cellulases, protease inhibitors etc., carbohydrates and other not yet identified components. Pharmacological studies relating to bromelain showed that only in very rare cases allergic reactions were observed. Moreover, these reactions normally wear off relatively quickly.

[0014] During the extensive studies leading to the present invention, it was now surprisingly found that administration of bromelain to patients reduced the onset and length of inflammatory diseases, and also improved the conditions during wound healing processes. Since bromelain as a food ingredient is well accepted by the body only minimal or no side effects are observed. This anti-inflammatory effect of bromelain is obviously mainly due to increasing the IL-8 secretion by cells of the immune system, which IL-8 secretion stimulates immune responses in an area of inflammation and attracts immune cells to said area by the process of chemotaxis. As a result of such a stimulation the immune processes involved in inflammatory processes may actually perform a quicker and more efficient task at the location of inflammation, so that the actual physiological conditions experienced by an individual suffering from an inflammatory condition are less severe and are reduced more quickly.

[0015] According to the invention a variety of different disease states may be treated that are based on inflammatory responses, such as psoriasis, rheumatoid arthritis, polyarthritis. Moreover, since the action of bromelain in reducing inflammation in an individual is based on an

stimulation of the individual's own immune system, said compound may well be utilized for an adjuvant therapy during wound healing processes and allergy.

[0016] On the other hand IL-8 is known to inhibit histamine release from basophil and mast cells and therefore antagonizes the IL-4 induced production of IgE by B-lymphocytes. Consequently, bromelain or components thereof is suitable as an anti-allergic agent, in particular as an anti-histaminikum.

[0017] The one or more of the components of bromelain is/are preferably non-protease component(s) thereof, since the stimulating activity of bromelain is even retained when bromelain has been subjected to high temperature treatment that

[0018] The invention will now be further described with reference to the following examples and to the drawing, wherein:

FIG. 1 shows the effects of bromelain BP (bromelain base powder) and heat inactivated bromelain on the secretion of IL-8 from neutrophils of healthy donors. Three independent experiments were performed.

Example

Effects of bromelain BP and of heat inactivated bromelain on the secretion of IL-8 from neutrophils

Bromelain Base Powder (BP)

[0019] Bromelain BP (purchased from CPC Wolfgang Mühlbauer GmbH, Hamburg, Germany) was dissolved in water and lyophilised. Proteolytic activity and protein content were determined by using the substrate L-Pyr-Phe-Leu-pNA (Harrach et al., J Protein Chem 14 (1995) 41-52) and the Bio-Rad Protein Assay (Bio-Rad Laboratories GmbH, München, Germany), respectively. Bromelain BP showed a specific activity of 0.34 U/mg. The protease activity was destroyed by heating the bromelain BP solution at 80 °C for 1 h.

Preparation of Neutrophils

[0020] Neutrophils were isolated by a single-step method as described by Ferrante et al. (J. Immunol. Methods. 36 (1980) 109).

[0021] About 20-30 ml of freshly isolated blood donated by a healthy volunteer was anticoagulated with preservative free heparin (10 U/ml final concentration, Sigma, Deisenhofen, Germany) and layered onto Polymorphprep (Nycomed Pharma, Oslo, Norway). After centrifugation (400 g, 30 min) at 20 °C the neutrophils were harvested from the second leukocyte band. One ml of water was added for 1 min to the cell suspension to lyse the erythrocytes. Cells were washed three times with PBS. Cell viability, determined by trypan blue exclusion, was found to be greater than 98 %.

Secretion of IL-8:

[0022] IL-8 was quantitated in cell-free supernatants using a sandwich enzyme immunoassay technique (R&D Systems, Minneapolis, USA). 2×10^5 neutrophils were incubated at 37 °C with or without test substance in microtiterplates having 96 wells. 24 hours incubation cells were centrifuged (400 x g, 7 min) and cell free supernatants were used. Samples and standards were pipetted into the IL-8 monoclonal antibody precoated wells and incubated 2.5 hours at room temperature. Then the cells were washed and the substrate solution was added. The colour development was stopped and determined using a microtiterplate reader (SLT Labinstruments, Austria).

Statistical analysis:

[0023] Statistical significance between treatment and control groups was calculated using the Mann-Whitney-Wilcoxon test and the computer programme Instat.

Experimental results:

[0024] Bromelain BP and heat inactivated bromelain were tested for their capability to increase the secretion of IL-8 in neutrophils.

[0025] Neutrophils were incubated with various amounts of bromelain BP and heat treated bromelain BP (range of 0.1 µg/ml - 100 µg bromelain BP) for a total of 24 hours. As can be seen in Fig. 1 bromelain BP and heat treated bromelain BP induced a significant increase in the secretion of IL-8 into the supernatant in a dose dependent manner, in the range of about 450 pg/ml - 2640 pg/ml IL-8. Neutrophils not activated with bromelain BP and heat inactivated bromelain did not show any IL-8 secreted into the supernatant.

[0026] Since also heat treated bromelain base powder was able to stimulate IL-8 secretion it may be concluded that the proteolytic activity does not correlate with the ability for neutrophil activation.

Claims

1. Use of bromelain and/or one or more components thereof for the manufacture of a medicament for increasing the IL-8 level in an individual.
2. The use according to claim 1, wherein functional capacities of granulocytes are stimulated.
3. The use according to claim 1 or claim 2, wherein the medicament is designed for the treatment of inflammatory diseases.
4. The use according to claim 1 or claim 2, wherein the medicament is designed for adjuvant therapy

during wound healing processes.

5. The use according to claim 3, wherein the inflammatory disease is associated with psoriasis, rheumatoid arthritis or polyarthritis or allergy. 5
6. The use according to claim 5, wherein the medicament is an anti-histaminikum.
7. The use according to any of the preceding claims, wherein the component of bromelain is a non-protease component thereof. 10

15

20

25

30

35

40

45

50

55




FIG. 1



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 12 5986

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 96 00082 A (CORTECS LTD ;MYNOTT TRACEY LEAHANNE (GB); ENGWERDA CHRISTIAN (GB)) 4 January 1996 (1996-01-04) * abstract * * page 1, line 3 - line 22 * * page 5, line 10 - line 17 * * page 8, line 20 - line 25 * * page 12, line 4 - page 13, line 4 * * page 44, line 25 - page 45, line 16 *	1-7	A61K38/48 A61P29/00 A61P37/00 A61P37/08 A61K35/78
A	TAUSSIG S J ET AL: "Bromelain, the enzyme complex of pineapple (ananas comosus) and its clinical application. An update" JOURNAL OF ETHNOPHARMACOLOGY, IE, ELSEVIER SCIENTIFIC PUBLISHERS LTD, vol. 22, no. 2, 1988, pages 191-203, XP002097864 ISSN: 0378-8741 * page 196, line 25 - page 197, line 5 * * page 200, line 5 - line 20 *	3-5	
A	ALAM R ET AL: "AGONISTIC-ANTAGONISTIC PROPERTY OF INTERLEUKIN 8 ON BASOPHILS IDENTIFICATION OF IL-8 AS A POTENT INHIBITOR OF CYTOKINE-INDUCED HISTAMINE RELEASE" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 87, no. 1 PART 2, 1991, page 241 XP001002229 ISSN: 0091-6749 * abstract *	1,2,6	<div>TECHNICAL FIELDS SEARCHED (Int.Cl.7)</div> <div>A61K</div>
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 7 June 2001	Examiner Noë, V
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		I : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date O : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1533 (03.92) (PAC01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 12 5986

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	THORNHILL S M ET AL: "Natural treatment of perennial allergic treatment" ALTERNATIVE MEDICINE REVIEW, vol. 5, 2000, pages 448-454, XP001002228 * abstract * * page 449, column 2, last paragraph * * page 451, column 2, paragraph 4 - page 452, column 2, paragraph 1; table 1 *	3,5,6	
A	EP 0 421 021 A (MUCOS EMULSIONS GMBH) 10 April 1991 (1991-04-10) * the whole document *		
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Place of search THE HAGUE		Date of completion of the search 7 June 2001	Examiner Noë, V
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPC FORM 1503 03/82 (P24C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 12 5986

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-06-2001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9600082 A	04-01-1996	AU 2749395 A	19-01-1996
		CA 2193654 A	04-01-1996
		CN 1151119 A	04-06-1997
		EP 0766565 A	09-04-1997
		FI 965204 A	21-02-1997
		JP 10502073 T	24-02-1998
		NO 965564 A	24-02-1997
		TW 403654 B	01-09-2000
EP 0421021 A	10-04-1991	NONE	

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82